Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1998 - Acute ototoxicity in adult cancer patients treated with platinum-based chemotherapy (532P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Ha-young Lee

Citation

Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676

Authors

H. Lee1, Y.H. Choi1, B. Seo1, K.A. Kwon1, S. An2, H.Y. Son2, H. Chang2, Y.S. Kim3

Author affiliations

  • 1 Medical Oncology, Dongnam Institute of Radological and Medical Sciences-DIRAMS, 619-953 - Busan/KR
  • 2 Otorhinolaryngology, Dongnam Institute of Radological and Medical Sciences-DIRAMS, 619-953 - Busan/KR
  • 3 Patient Education Team, Dongnam Institute of Radological and Medical Sciences-DIRAMS, 619-953 - Busan/KR
More

Resources

Abstract 1998

Background

Platinum-based chemotherapy is widely used and effective as antineoplastic agents. They are also considered to be potentially highly ototoxic. Effects of platinium-based chemotherapy on hearing loss have been evaluated in childhood cancer patients and survivors but not in adult cancer patients and patients undergoing platinum-based chemotherapy.

Methods

We analyzed the clinical data and acute ototoxicity of adult patients with solid cancer receiving platinum-based chemotherapy in Dongnam Institution of Radiological and Medical Sciences(DIRAMS).

Results

This study included 130 patients treated with platinum-based chemotherapy for malignancy in DIRAMS from July 2016 to March 2017. Hearing was assessed by pure tone audiometry (0.25 to 8 kHz) in 0,1,2,3 months after starting platinum. Absolute hearing loss (AHL) was defined as thresholds of > 20 dB at any frequency. AHL was identified in 59 cases (45%) at baseline, 58 cases (45%) at 1month, 38/91 cases (42%) at 2 months and 26/64 cases (41%) at 3 months. The number of patients who received cisplatin, which is more highly ototoxic than other platinum agents, was 78 (60%). In patients receiving cisplatin, AHL was identified in 33 cases (44%) at baseline, 32 cases (41%) at 1 month, 18/50 cases (36%) at 2 months and 14/33 cases (42%) at 3 months. Cumulative cisplatin doses were not associated with hearing loss.

Conclusions

In this study, adult cancer patients undergoing platinum-based chemotherapy have no significant hearing loss. So, acute ototoxicity of platinum was not shown. We do not clearly know when platinuminduced hearing loss will occur. Therefore, long term follow-up of adult cancer patients receiving platinum-based chemotherapy is needed.

Clinical trial identification

Legal entity responsible for the study

DIRAMS

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.